15% off first order with code: 1storder
Competitive Prices
Pulmonary fibrosis is a serious lung disease that causes permanent damage and scarring of the lung tissue. As this disease gets worse, it makes it harder to breathe because the lungs become stiff and unable to work properly.
Over time, this can lead to severe difficulty breathing and, in some cases, death. Pulmonary fibrosis can be caused by several factors, including diseases like idiopathic pulmonary fibrosis (IPF), exposure to harmful environmental pollutants, certain autoimmune diseases, and even some medications.
Unfortunately, in many cases, the exact cause of the disease is not known, which makes it even harder to treat. Currently, there are treatments that can slow down the disease, but they mostly focus on easing symptoms rather than stopping or fixing the damage.
This has led researchers to look for new treatments, and one of the most exciting areas of research is using peptides like FOXO4-DRI. These peptides have shown great potential in lab studies, offering hope that they might help treat or even reverse pulmonary fibrosis in the future.
Explore VIP Peptide from Pharma Lab Global, known for easing airway constriction and reducing inflammation to support lung function.
Pulmonary fibrosis is a condition where lung tissue becomes scarred and thick, a process called fibrosis. When the lungs are damaged by injury or disease, they try to heal by forming scar tissue. However, this scar tissue builds up over time and makes the lungs stiffer, meaning they can’t expand and contract like they should.
As the disease progresses, may experience symptoms like chronic coughing, shortness of breath, tiredness, and trouble doing physical activities. The most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF), which means doctors don’t know exactly what causes it.
Still, things like pollution, chemicals, viruses, and genetic changes are thought to play a part in its development. There is no cure for pulmonary fibrosis, and while treatments can help slow the disease down, they can’t undo the damage.
This is why researchers are looking into new approaches, like using peptides, to help treat the disease.
FOXO4-DRI is a type of peptide that has recently been studied for its ability to help treat pulmonary fibrosis. It works by focusing on something called “cellular senescence,” which plays a big role in how the disease progresses.
Senescent cells are cells that have stopped dividing, usually due to stress, damage, or aging. Instead of dying like they should, these cells stay alive and build up in tissues. They also release substances that cause inflammation and worsen fibrosis in the lungs.
FOXO4-DRI helps by targeting and getting rid of these senescent cells. It works by binding to a protein called FOXO4, which helps senescent cells survive.
By blocking this protein, FOXO4-DRI causes these cells to die off, reducing inflammation and preventing further scarring in the lungs. Early Singapore studies in animals have shown that FOXO4-DRI can slow down the scarring process in the lungs, which could be a big step forward for treating the disease.
However, it’s important to know that FOXO4-DRI is still in the research phase and has not been tested on humans yet. More studies are needed to figure out if it is safe and effective for human use.
Explore FOXO4-DRI from Pharma Lab Global Singapore, a peptide that targets senescent cells, potentially slowing or reversing pulmonary fibrosis and improving lung health.
Senescent cells are a big problem in pulmonary fibrosis because they continue to cause damage even after they should have died off. They release molecules that promote inflammation and fibrosis, making the disease worse.
By focusing on these cells, FOXO4-DRI could offer a new way to stop or even reverse some of the damage caused by the disease. Instead of just treating the symptoms, FOXO4-DRI targets the root cause of the fibrosis, making it a more effective approach than the treatments we have now.
Removing these senescent cells doesn’t just help with pulmonary fibrosis. It could also help treat other diseases that come with aging or damage to the body, like heart disease, cancer, and brain disorders. FOXO4-DRI could become an important part of future treatments for many diseases.
Along with FOXO4-DRI, another peptide being studied for pulmonary fibrosis is Vasoactive Intestinal Peptide (VIP). VIP is a naturally occurring neuropeptide found in the lungs that helps regulate inflammation, immune activity and airway function. These roles make it relevant in conditions where inflammation drives tissue damage.
Research shows that VIP has strong anti-inflammatory and immunomodulatory effects. In preclinical studies, it has been shown to reduce inflammatory signaling, limit oxidative stress and decrease processes like epithelial mesenchymal transition that contribute to lung scarring. These effects may help slow fibrosis progression and protect lung structure.
However, most evidence comes from laboratory and animal studies. While early research in other respiratory conditions exists, its effectiveness in pulmonary fibrosis remains under investigation and requires further clinical validation.
Discover VIP Peptide from Pharma Lab Global Singapore, a neuropeptide known for its ability to reduce inflammation and promote tissue repair, supporting improved lung function.
Bronchogen is a tetrapeptide studied for its effects on bronchial epithelium and lung inflammation. Preclinical research shows it can reduce epithelial remodeling and restore normal cell composition, including ciliated cells, while lowering inflammatory activity.
It has also been shown to influence the expression of differentiation factors in bronchial epithelial cells, suggesting a role in regulating cellular function and tissue organization.
These findings come from preclinical and cellular studies and indicate that peptide-based approaches like Bronchogen may target structural and functional aspects of lung tissue.
Discover Bronchogen from Pharma Lab Global Singapore, studied for its effects on bronchial epithelial structure and its role in supporting normal lung tissue function.
Peptides like FOXO4-DRI, VIP and Bronchogen offer a more targeted approach to pulmonary fibrosis compared to traditional treatments. Instead of affecting many different parts of the body, these compounds are designed to interact with specific molecules or cells involved in disease progression.
By focusing on biological processes such as senescent cell accumulation, inflammation and epithelial changes, these approaches may help slow disease progression and support normal lung structure.
As research continues, these strategies may contribute to more targeted and personalized approaches to managing pulmonary fibrosis.
However, it’s important to remember that these approaches are still under investigation and more research is needed to better understand their safety and effectiveness.
While the research on FOXO4-DRI, VIP and Bronchogen is promising, these peptides are still in the early stages of development. More clinical trials will be needed to determine if they are safe and effective for humans.
In animal studies, FOXO4-DRI has been shown to reduce lung fibrosis and improve lung function, but we need more data from human trials to understand its full effects.
VIP is also still being studied in labs, and although animal models have shown good results, human trials are needed to confirm its safety and effectiveness.
In the future, we may see combination treatments that use FOXO4-DRI along with other drugs or peptides to treat multiple causes of pulmonary fibrosis.
As research continues, these approaches suggest a shift toward more targeted and science based strategies. Although still in early stages, this progress offers a clearer path toward better ways to understand and manage a complex disease.
Explore peptide research Consumables for all your reconstitution requirements.
Buy FOXO4-DRI Peptide Online
Pharma Lab Global is one of the best locations to purchase high purity FOXO4-DRI peptides for research. Pharma Lab Global is a trusted supplier of peptides worldwide.
(1) Han X, Yuan T, Zhang J, Shi Y, Li D, Dong Y, Fan S. FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. J Cell Mol Med. 2022 Jun;26(11):3269-3280.
(2) Correction to “FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway”Han XD, Yuan T, Zhang JL, et al. FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. J Cell Mol Med. 2022;26(11):3269-3280. J Cell Mol Med. 2024 Aug;28(16):e18502.
(3) Han X, Yuan T, Zhang J, Shi Y, Li D, Dong Y, Fan S. FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. J Cell Mol Med. 2022 Jun;26(11):3269-3280. doi: 10.1111/jcmm.17333. Epub 2022 May 5. Erratum in: J Cell Mol Med. 2024 Aug;28(16):e18502.
Pulmonary Fibrosis FAQs
What is pulmonary fibrosis?
The thickening and scarring (fibrosis) of lung tissue is the hallmark of pulmonary fibrosis, a chronic lung disease. The lungs’ capacity to expand and absorb oxygen is diminished as a result of this scarring. Shortness of breath, a persistent dry cough, exhaustion, soreness in the chest, and, in more severe cases, clubbing of the fingers are symptoms that arise as oxygen becomes more difficult to enter the bloodstream.
What causes pulmonary fibrosis?
Long-term exposure to environmental pollutants (such as silica and asbestos), certain drugs, radiation therapy, autoimmune illnesses, or infections are some of the causes of the condition. However, the term “idiopathic pulmonary fibrosis” (IPF) refers to a condition in which the cause is frequently unknown. Although there is presently no cure for pulmonary fibrosis, therapies include oxygen therapy, medicines, and, in extreme situations, lung transplants can help control symptoms and enhance quality of life.
What are senescent cells?
Senescent cells are aged or damaged cells that have stopped dividing but do not die off as they normally should. While they no longer function properly, they remain metabolically active and can release inflammatory signals and harmful molecules, known as the senescence-associated secretory phenotype (SASP). These signals can damage surrounding healthy cells and contribute to chronic inflammation.
Senescent cells play a dual role in the body. In small amounts, they help with wound healing and preventing cancer by halting the growth of damaged cells. However, when they accumulate over time, especially with aging, they are linked to age-related diseases like arthritis, cardiovascular issues, and neurodegeneration. Research into therapies targeting senescent cells, called senolytics, aims to remove these cells and potentially slow aging and improve healthspan.
What’s the difference between cystic fibrosis and pulmonary fibrosis?
Cystic fibrosis (CF) and pulmonary fibrosis (PF) are distinct lung conditions. CF is a genetic disorder caused by CFTR gene mutations, leading to thick mucus build up in the lungs and digestive system. It typically appears in childhood and causes persistent cough, lung infections, and digestive issues. PF, on the other hand, involves scarring of lung tissue, often due to environmental exposures, autoimmune diseases, or unknown causes, and usually develops later in life. Symptoms include shortness of breath and dry cough. While CF treatments focus on clearing mucus and preventing infections, PF treatments aim to slow scarring and manage symptoms.
Can peptides can ease pulmonary fibrosis?
Because peptides can target particular biological processes, they are being investigated as a potential treatment for pulmonary fibrosis (PF). In preclinical research, some peptides have demonstrated potential in lowering inflammation, preventing excessive scarring (fibrosis), and encouraging tissue healing. For instance, certain peptides may minimize lung damage by modulating immune responses or blocking the function of transforming growth factor-beta (TGF-β), a major cause of fibrosis.
Peptide-based medicines are not yet widely accessible or licensed for the treatment of PF, despite continuous research. Antifibrotic drugs, oxygen therapy, and supportive care are the mainstays of current PF treatment. To verify the efficacy and safety of peptides, clinical trials are crucial.
ALL PRODUCT INFORMATION AND ARTICLES ON THIS SITE ARE FOR EDUCATIONAL PURPOSES ONLY
DISCLAIMER: All products sold by Pharma Lab Global are for research and laboratory use only. These products are not designed for use or consumption by humans or animals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such. By purchasing from our Website the buyer accepts and acknowledges the risks involved with handling of these products. All articles and product information provided on this Website are for informational and educational purposes only. Handling and use of these products should be restricted to suitably qualified professionals.
Humanin for Age-Related Diseases: Can It Offer a Solution Singapore? Age-related diseases are a growing concern globally, affecting millions as
What Are the Best Peptides for Osteoarthritis Joint Pain Singapore ? Osteoarthritis joint pain often begins with mild stiffness, but
L-Glutathione for Skin Whitening: Myth or Miracle? L-Glutathione is studied in dermatology for its role in melanin regulation and the
